Cardiff Oncology (NASDAQ:CRDF) Rating Reiterated by HC Wainwright

Cardiff Oncology (NASDAQ:CRDF)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 322.96% from the stock’s previous close.

Separately, Piper Sandler increased their price target on shares of Cardiff Oncology from $5.00 to $7.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st.

Cardiff Oncology Trading Down 4.3 %

CRDF opened at $3.31 on Monday. The stock’s 50 day simple moving average is $4.60 and its 200-day simple moving average is $2.53. The stock has a market cap of $148.02 million, a PE ratio of -3.68 and a beta of 2.02. Cardiff Oncology has a 1 year low of $0.94 and a 1 year high of $6.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. Cardiff Oncology had a negative net margin of 6,594.92% and a negative return on equity of 54.54%. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.08 million. Equities analysts forecast that Cardiff Oncology will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. PFG Investments LLC acquired a new stake in shares of Cardiff Oncology during the 1st quarter worth about $53,000. Callan Capital LLC grew its stake in Cardiff Oncology by 129.2% during the third quarter. Callan Capital LLC now owns 31,147 shares of the company’s stock worth $43,000 after buying an additional 17,560 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Cardiff Oncology during the first quarter worth approximately $1,351,000. 16.29% of the stock is owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.